
Merck has completed its roughly $9.2 billion acquisition of Cidara Therapeutics, the Sorrento Valley biotech behind an experimental flu drug that could offer months of protection from a single shot. The deal, finalized in January 2026 after a cash tender offer, hands the pharmaceutical giant control of CD388, a non-vaccine antiviral that posted striking early results against seasonal influenza in healthy adults. But the drug's real test, researchers caution, still lies ahead with the patients who need protection the most.
Merck's tender offer paid $221.50 per share, and according to Merck, 27,149,333 shares of Cidara common stock were tendered, representing approximately 85.96% of the company's outstanding shares. Cidara is headquartered in San Diego, California, according to Cidara Therapeutics via GlobeNewswire. The deal closed with conditions that included Cidara stockholders tendering their shares and the expiration of the federal Hart-Scott-Rodino antitrust waiting period, per the same company's earlier statement on the acquisition agreement.
How CD388 Works
CD388 is built differently than a typical flu shot. It links zanamivir, the antiviral compound found in the decades-old drug Relenza, to an engineered fragment of a human antibody, according to San Diego Magazine. That antibody fragment is designed to keep the drug circulating in the bloodstream for months, while the zanamivir component targets neuraminidase, an enzyme flu viruses rely on to release new copies of themselves and spread through the body. Both Tamiflu and Relenza have targeted that same enzyme since the late 1990s, per the magazine's reporting, but CD388's antibody-linked design is meant to let a single injection cover most of a flu season.
Cidara has described CD388 as intended for universal prevention of seasonal and pandemic flu, and laboratory research cited by the company suggests the drug acts against a broad range of influenza A and B viruses. That preclinical picture gets some support from Nature Microbiology, which reported that CD388 demonstrated activity across influenza A and B viruses in testing, including highly pathogenic and neuraminidase-inhibitor-resistant strains.
What the Trial Actually Showed
Cidara reported trial data in summer 2025 from its Phase 2b NAVIGATE study, which involved more than 5,000 healthy, unvaccinated adults. The trial enrolled 5,071 participants aged 18 to 64 at 57 U.S. sites and one U.K. site, according to CIDRAP. Participants received a single dose of CD388 before flu exposure, and the trial measured reductions in symptomatic, lab-confirmed flu compared with placebo over 24 weeks.
The highest dose tested, 450 milligrams, showed 76.1% prevention efficacy versus placebo, a statistically significant result, per Contagion Live. A secondary analysis in the trial found that protection was maintained with statistical significance for up to 28 weeks, close to seven months, the outlet reported. The trial also reported no serious side effects tied to CD388.
Why Doctors Are Urging Caution
Dr. Laya Reddy, cited in San Diego Magazine's reporting, cautioned that the word universal describes CD388's intended mechanism rather than a proven result. She said the preliminary results are promising, but that broad protection seen in laboratory tests does not prove protection for every patient across a full flu season. Reddy noted that strong data exists so far only in healthy adults, not yet in the populations who need protection most.
That distinction matters because the NAVIGATE trial was not designed to determine whether CD388 prevents hospitalization or death, or how it performs in higher-risk people, per the magazine's reporting. Reddy also pointed out that people for whom influenza is most dangerous tend to be the same people for whom vaccines underperform, and said influenza can develop resistance to antivirals as the virus evolves under pressure. She described CD388 as realistically a complement to vaccines rather than a replacement — another tool, particularly for people whom vaccines serve poorly.
The Next Test: Phase 3 ANCHOR
Merck's Phase 3 ANCHOR study is now attempting to answer the question NAVIGATE could not. The trial is testing CD388 in adults and adolescents at higher risk of severe flu complications, with a target enrollment of 6,000 participants; the first participants were dosed in September 2025, according to Merck. ANCHOR will determine whether CD388's protection holds up in that higher-risk group.
The FDA granted CD388 Breakthrough Therapy Designation in October 2025, a status Merck highlighted in announcing the Cidara deal. Merck's own release points to the scale of the problem the drug is aimed at: seasonal influenza infects an estimated 1 billion people globally each year and causes an estimated 290,000 to 650,000 deaths worldwide annually, the company said. Existing antivirals do shorten illness and reduce severity and duration of symptoms in people already sick with the flu, but CD388 is designed to prevent illness in the first place rather than treat it after infection — and it is not a vaccine. Modern influenza vaccines first arrived in the 1940s, and their effectiveness has varied widely since: a CIDRAP report citing CDC data found flu vaccine effectiveness ranged from 19% to 60% across the past 15 flu seasons, underscoring why researchers see room for additional tools even as they stress that CD388 remains unproven outside the population it has so far been tested in.









